Feasibility of Novel Diagnostics for TB in Endemic Countries (FEND for TB) (R01 Clinical Trial Not Allowed)
Funding Opportunity RFA-AI-24-010 from the NIH Guide for Grants and Contracts. The purpose of this notice of funding opportunity (NOFO) is to support the evaluation of early-stage diagnostics and novel diagnostic strategies for Tuberculosis (TB) in the context of existing clinical algorithms in TB endemic countries. Evaluation studies should: 1) perform proof-of principle studies of novel diagnostic tests and strategies for TB, including among people living with HIV (PLWH) and 2) provide feedback to diagnostic developers and policy makers on the performance of the technologies and most effective strategies for use of th...
Source: NIH Funding Opportunities (Notices, PA, RFA) - March 27, 2024 Category: Research Source Type: funding
Request for Information (RFI): Inviting Comments and Suggestions on Updating the NIAID Strategic Plan for Tuberculosis Research
Notice NOT-AI-23-052 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - June 13, 2023 Category: Research Source Type: funding
Analyzing Early Events in TB and TB/HIV Infection for Interventional Targets (R01 Clinical Trial Not Allowed)
Funding Opportunity RFA-AI-23-029 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support mechanistic studies of the early stage of Mycobacterium tuberculosis (Mtb) infection, with and without HIV, to identify interventional targets for vaccine and host-directed therapies. (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - May 15, 2023 Category: Research Source Type: funding
Pulmonary Outcomes and Sequelae after Treatment-TB (POST-TB) (R01 Clinical Trial Optional)
Funding Opportunity PAR-23-148 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support applications for epidemiological and observational research projects on the long-term cardiopulmonary sequelae following treatment for tuberculosis (TB). Investigators should propose additional testing and data collection in existing cohorts of adult and/or pediatric TB participants to better characterize and understand adverse outcomes and morbidity associated with TB disease post treatment in individuals with and without HIV infection. (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - March 30, 2023 Category: Research Source Type: funding
Consortium for Design of TB Drug Regimens (UM1 Clinical Trial Not Allowed)
Funding Opportunity RFA-AI-22-059 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to establish a consortium of tuberculosis (TB) preclinical and clinical experts to systematically refine preclinical models by analyses of relevant pre-clinical and clinical data, and to provide results from optimized models to identify the most promising combination regimens for clinical testing (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - September 21, 2022 Category: Research Source Type: funding
Notice of Special Interest (NOSI): Halting Tuberculosis (TB) Transmission
Notice NOT-AI-22-064 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - September 20, 2022 Category: Research Source Type: funding
Pre-Solicitation Notice: Mycobacterium Tuberculosis (MTB) Quality Assessment Program (TBQA), RFP: 75N93022R00015
Notice NOT-AI-22-073 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - August 26, 2022 Category: Research Source Type: funding
Identifying Host Cell Death Pathway Targets for Host-Directed Therapies for Treatment of Mtb and Mtb/HIV Co-Infection (R01 Clinical Trial Not Allowed)
Funding Opportunity PAR-22-223 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support mechanistic studies on host cell death pathways and immune responses to Mycobacterium tuberculosis (Mtb) and Mtb/HIV co-infection to identify immune targets for development of host-directed therapies. (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - August 9, 2022 Category: Research Source Type: funding
Resources Access for Preclinical Integrated Drug Development (RAPIDD) Program (X01 Clinical Trial Not Allowed)
Funding Opportunity PAR-22-185 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to provide a method for investigators to request gap filling preclinical services to academic and private institutions to assist with product development efforts and facilitate the advancement of promising therapeutics for HIV and HIV-associated co-infections (Hepatitis B, Hepatitis C and Tuberculosis). (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - May 27, 2022 Category: Research Source Type: funding
NIH All About Grants Podcast: Building Bridges
Bonnie Burgess-Beusse, Ph.D., Program Director: Division of Digestive Diseases and Nutrition, NIDDK, NIH
Lakshmi Ramachandra, Ph.D., Section Chief; Tuberculosis Research Advancement Centers, NIAID, NIH
You may have heard that NIH can provide limited, interim research support for applications with creative and innovative approaches that fell just outside the payline. These “bridge awards” are helpful for researchers to gather additional data to revise their current application. But, how do we decide on which applications to support this way?
Join us for this NIH All About Grants podcast episode to learn more about R56/b...
Source: NIH Extramural Nexus - May 12, 2022 Category: Research Authors: NIH Staff Tags: New Resources Bridge Awards podcast Source Type: funding
Improved Drug Susceptibility Testing (DST) for Tuberculosis (R01 Clinical Trial Not Allowed)
Funding Opportunity RFA-AI-22-016 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support the development of new diagnostic technologies for tuberculosis (TB) drug susceptibility testing (DST), including point of care (POC) DST and companion diagnostics for new TB drugs. (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - March 2, 2022 Category: Research Source Type: funding
Biomarker Signatures of TB Infection in Young Children With and Without HIV (R01 Clinical Trial Not Allowed)
Funding Opportunity RFA-AI-22-015 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to advance research to discover and validate novel biomarkers of Tuberculosis (TB) infection and subsequent risk of progression to TB disease in young children with and without HIV. (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - February 9, 2022 Category: Research Source Type: funding
RePORT International Coordinating Center (RICC) (U01 Clinical Trial Not Allowed)
Funding Opportunity RFA-AI-21-078 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications for a Regional Prospective Observational Research in Tuberculosis (RePORT) International Coordinating Center (RICC) for the global RePORT networks, whose mission is to advance regional and international TB and TB/HIV science, strengthen TB/HIV research capacity and infrastructure, and foster research collaboration. The RICC will coordinate the planning and implementation of research in TB and TB/HIV across all the RePORT networks and establish and maintain t...
Source: NIH Funding Opportunities (Notices, PA, RFA) - November 2, 2021 Category: Research Source Type: funding
Brazil Regional Prospective Observational Research in Tuberculosis (RePORT) (U01 Clinical Trial Not Allowed)
Funding Opportunity PAR-21-304 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) will support a Brazil-US Regional Prospective Observational Research in Tuberculosis (RePORT) network that will leverage the robust clinical research infrastructure of Brazil to advance our current understanding of the community, host and microbial factors that impact outcomes of tuberculosis (TB) infection and TB disease, especially among persons with HIV (PWH), including drug-resistant TB, to facilitate development of tools to improve treatment outcomes at the individual level and to inform strategie...
Source: NIH Funding Opportunities (Notices, PA, RFA) - August 5, 2021 Category: Research Source Type: funding
Innovation for Tuberculosis Vaccine Discovery (ITVD) (R61/R33 Clinical Trial Not Allowed)
Funding Opportunity RFA-AI-21-007 from the NIH Guide for Grants and Contracts. To support the design of novel tuberculosis (TB) vaccine candidates that exploit innovative approaches and their advancement into preclinical animal model testing. This funding opportunity will use a milestone driven, biphasic award mechanism to fund high risk/exploratory research. Transition to the second phase depends on the successful completion of milestones. (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - February 19, 2021 Category: Research Source Type: funding
